Publications by authors named "Julia de Oliveira Machado"
Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.
Alisson Pugliesi Daniela Gomes Chicre Oliveira Vani Abreu de Souza Filho Júlia de Oliveira Machado Aline Gonçalves Pereira
Semin Arthritis Rheum
December 2024
Article Synopsis
- The study compared the risks of major adverse cardiovascular events (MACE) and all-cause death (ACD) in rheumatoid arthritis patients treated with JAK inhibitors (JAKi) or tocilizumab (TCZ) versus tumor necrosis factor inhibitors (TNFi).
- A systematic review of randomized controlled trials showed that JAKi were associated with a non-significant increase in risks for MACE and ACD compared to TNFi, with Bayesian analysis indicating a higher probability of these events occurring with JAKi.
- The analysis highlighted the need for more data, particularly on JAKi other than tofacitinib, to make informed regulatory recommendations regarding their use.